May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema: Results of the Pan-American Collaborative Retina Study Group at 6-Months Follow-Up
J. Arevalo; J. Fromow-Guerra; H. Quiroz-Mercado; J. G. Sanchez; L. Wu; M. Maia; M. H. Berrocal; A. Solis-Vivanco; M. E. Farah; Pan-American Collaborative Retina Study Group (PACORES)
Author Affiliations & Notes
  • J. Arevalo
    Retina and Vitreous, Clinica Oftal Centro Caracas, Caracas, Venezuela
  • J. Fromow-Guerra
    Retina and Vitreous, Asociacion Para Evitar la Ceguera, Mexico City, Mexico
  • H. Quiroz-Mercado
    Retina and Vitreous, Asociacion Para Evitar la Ceguera, Mexico City, Mexico
  • J. G. Sanchez
    Retina and Vitreous, Clinica Oftal Centro Caracas, Caracas, Venezuela
  • L. Wu
    Retina and Vitreous, Instituto de Cirugia Ocular, San Jose, Costa Rica
  • M. Maia
    Departamento de Oftalmologia, Universidade Federal de São Paulo - Instituto da Visão, São Paulo, Brazil
  • M. H. Berrocal
    Retina and Vitreous, University of Puerto Rico, San Juan, Puerto Rico
  • A. Solis-Vivanco
    Retina and Vitreous, Asociacion Para Evitar la Ceguera, Mexico City, Mexico
  • M. E. Farah
    Departamento de Oftalmologia, Universidade Federal de São Paulo - Instituto da Visão, São Paulo, Brazil
  • Pan-American Collaborative Retina Study Group (PACORES)
    Retina and Vitreous, Clinica Oftal Centro Caracas, Caracas, Venezuela
  • Footnotes
    Commercial Relationships J. Arevalo, Pfizer, C; Alcon Labs., R; J. Fromow-Guerra, None; H. Quiroz-Mercado, None; J.G. Sanchez, None; L. Wu, Pfizer, C; M. Maia, None; M.H. Berrocal, Alcon Labs., R; A. Solis-Vivanco, None; M.E. Farah, None.
  • Footnotes
    Support Supported in part by the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5027. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema: Results of the Pan-American Collaborative Retina Study Group at 6-Months Follow-Up
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      J. Arevalo, J. Fromow-Guerra, H. Quiroz-Mercado, J. G. Sanchez, L. Wu, M. Maia, M. H. Berrocal, A. Solis-Vivanco, M. E. Farah, Pan-American Collaborative Retina Study Group (PACORES); Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema: Results of the Pan-American Collaborative Retina Study Group at 6-Months Follow-Up. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5027.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose:: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal (IVT) bevacizumab (Avastin) in patients with diabetic macular edema (DME).

Methods:: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of six months and a mean age of 59.7 ± 9.3 years old were included in this analysis. Patients were treated with at least one IVT injection of 1.25 mg or 2.5 mg of bevacizumab. Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated measures analysis of variance was used to compare mean values. Main outcome measures included changes in BCVA, OCT and FA.

Results:: Mean follow-up was 6.31 ± 0.81 months (range from 6 to 9 months). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range from 4 to 28 weeks), and six eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range from 5 to 20 weeks). The mean baseline BCVA was logMAR = 0.87 and the final mean BCVA was logMAR = 0.6, a difference that was statistically significant (p < 0.0001). Final BCVA analysis demonstrated that 32 (41.1%) eyes remained stable, 43 (55.1%) eyes improved two or more ETDRS lines of BCVA, and 3 (3.8%) eyes decreased two or more ETDRS lines of BCVA. The mean central macular thickness at baseline by OCT was 387.0 µm ± 182.8 µm and decreased to a mean of 275.7 µm ± 108.3 at the end of follow-up (p < 0.0001). No ocular or systemic adverse events were observed.

Conclusions:: Primary IVT bevacizumab at doses of 1.25 mg or 2.5 mg seem to provide stability or improvement in VA, OCT and FA in DME at 6-months. Follow-up is still short to make any specific treatment recommendations, however the results appear promising. Evaluation in a multicenter, randomized, controlled clinical trial with longer follow-up is needed.

Keywords: diabetic retinopathy • macula/fovea • injection 
© 2007, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept